FOLLOW UP FOR NEEDLE EXCHANGE TRIAL

这项竞争性的继续申请是为了完成在阿拉斯加安克雷奇进行的第一项针具交换随机对照试验的随访。 本研究采用了两组随机临床试验的设计，其中目前的注射吸毒者被随机分配到：（a）能够使用注射器交换（在三个不同地点中的任何一个），或（B）无法使用注射器交换，并被告知如何使用法律的药房销售。 到第一年的延续结束时，所有受试者都将接受6个月和12个月的随访。 将通过风险行为随访评估（RBFA）收集信息，这是一份关于针头使用和采购的补充问卷，安非他明、可卡因代谢物和吗啡的尿液检测，以及丙型肝炎病毒和B型肝炎病毒的血清学检测。 还将监测人体免疫缺陷病毒的标志物。数据安全和监测委员会将继续至少每六个月举行一次会议，并监督研究中涉及的伦理问题。

This competing continuation application is to complete follow-up for the first randomized controlled trial of needle exchange that is taking place in Anchorage Alaska. This research uses the design of a two group randomized clinical trial in which current injection drug users have been randomly assigned to: (a) being able to use syringe exchange (at any of three different locations), or (b) not having access to the syringe exchange and being instructed how to use legal pharmacy sales instead. By the time the first year of this continuation ends, all subjects will have had six-month and 12-month follow-up. Information will be collected with the Risk Behavior Follow-Up Assessment (RBFA), a supplementary questionnaire concerning needle use and procurement, urine testing for amphetamines, cocaine metabolites, and morphine, and serological testing for Hepatitis C Virus, and Hepatitis B Virus. Markers of Human Immunodeficiency Virus will also be monitored. A Data Safety and Monitoring Board will continue to meet at least every six months and have oversight over the ethical issues involved in the research.